SF3B1 and myelodysplastic syndrome: Another option for patients with MDS, particularly with RS—generally associated with mutations in SF3B1—who experience disease progression with ESA treatment, is luspatercept, which targets pathways associated with TGF-β signaling and enhances late-stage erythroid maturation [16].